MedPath

Effect of Ketoconazole on Biliary Excretion of AZD0837

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT00812344
Lead Sponsor
AstraZeneca
Brief Summary

This is an explorative study and the scientific question to be investigated is if the biliary excretion of AZD0837 and its metabolites AR-H069927XX and AR-H067637XX are affected by co-administration with ketoconazole

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
Exclusion Criteria
  • Significant illness, trauma or surgical procedures.
  • Clinically significant laboratory abnormalities.
  • Clinically significant medical history

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1AZD0837-
2AZD0837AZD0837 + Ketoconazole
2ketoconazoleAZD0837 + Ketoconazole
Primary Outcome Measures
NameTimeMethod
Amount of AZD0837, AR-H069927XX, and AR-H067637XX in bile and biliary clearance of AZD0837, AR-H069927XX, and AR-H067637XX.Frequent sampling through a Loc-I-Gut catheter for up to 3 hours post dose.
Secondary Outcome Measures
NameTimeMethod
PK variables of AZD0837, AR-H069927XX, and AR-H067637XX.Frequent sampling during 24 hours.
Adverse events, physical examination, safety laboratory variables, blood pressure, pulse and electrocardiography.Some of the safety variables will be followed at each visit, some less frequent.
PharmacogeneticsOne sampling during the study.

Trial Locations

Locations (1)

Research Site

πŸ‡ΈπŸ‡ͺ

Uppsala, Sweden

Β© Copyright 2025. All Rights Reserved by MedPath